Azra Dzalic
Houston, TXNPI 1275152613
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (37.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by United Therapeutics Corporation at 59.0% of the total.
Across 238 payments — averaging $85.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$12K
- Merck$3K
- Actelion Pharmaceuticals US, Inc.$2K
- Bayer$1K
- Boehringer Ingelheim$383
- AstraZeneca$361
- plus $2K from 15 others
What the payments were for
- Consulting fees$7,67038%
- Travel & lodging$5,11425%
- Food & beverage$7,39736%
- Education$2681%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 75 | $12,073 |
| Merck | 18 | $2,627 |
| Actelion Pharmaceuticals US, Inc. | 43 | $2,073 |
| Bayer | 17 | $1,052 |
| Boehringer Ingelheim | 14 | $383 |
| AstraZeneca(2 entities) | 4 | $361 |
| Johnson & Johnson | 4 | $330 |
| AbbVie | 13 | $269 |
| Grifols USA, LLC | 10 | $258 |
| Irhythm Technologies, Inc. | 8 | $163 |
| Astellas Pharma US Inc | 6 | $154 |
| Inari Medical, Inc. | 1 | $132 |
| Sandoz | 8 | $126 |
| Abiomed | 1 | $115 |
| Baxter Healthcare | 5 | $97 |
| Alnylam Pharmaceuticals Inc. | 3 | $84 |
| Regeneron Healthcare Solutions, Inc. | 2 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Smith+Nephew | 2 | $28 |
| Convatec Inc. | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REMODULIN$3,109
- WINREVAIR$1,034
- UPTRAVI$896
- Adempas$844
- OPSUMIT$471
- FLOWTRIEVER CATHETER, S$132
- CT THROMBECTOMY SYSTEM KIT$132
- FASENRA$125
- XARELTO$120
- TEZSPIRE$117
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $8,065 |
| Sildenafil Citrate | 21 | $3,526 |
| Potassium Chloride | 18 | $160 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.